Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

Why is Rivian building a new factory now? How will Trump’s quarterly reporting proposal impact investors? What drove gold prices above $3,700 recently? Why is Tesla under investigation for door handle defects? How did TikTok reach a US-China framework deal? What’s behind Amazon’s Prime Big Deal Days timing? Why is the Federal Reserve expected to cut rates?

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

benzinga.com/analyst-stock-ratings/price-target/25/09/47628962/analysts-raise-price-targets-following-strong-data-from-revolution-medicines-p

Revolution Medicines, Inc. (NASDAQ:RVMD) stock is trading higher after the company shared updates from its Daraxonrasib Phase 1 trials on Wednesday.
As of the June 30, 2025, cutoff date, daraxonrasib monotherapy data from long-term follow-up in second-line (2L) metastatic pancreatic…

This story appeared on benzinga.com, 2025-09-11 18:14:44.